



PRESS RELEASE: Paris November 30, 2020: Telesphore Pharma, the 2nd BMSystems' therapeutic spin-off is selected by the Biofit 2020 steering committee to pitch its First-in-class "Disease Centric Repositioning" Diagnosis and Treatment.

Telesphore Pharma that addresses Chronic Low-Grade Inflammatory Disorders (CLGIDs) with a First in class treatment for ME/CFS and a group of Post Covid-19 "long-haulers" is proud to be the only start-up selected to pitch *in the current critical "inflammation" track at Biofit 2020 on December 9, 5-6:30 pm.*

Its first objective is to transform for the first time Myalgic Encephalomyelitis / Chronic Fatigue Syndrome from a syndrome that lacks concrete diagnostic criteria and treatment, into a universally recognizable, diagnosable and treatable organic disease.

Telesphore Pharma key factors of success:

1. **CADI-T1031 Diagnostic/Treatment:** First-in-class "*Disease centric repositioning*" Diagnosis and Treatment derive from the understanding of the causal mechanism of the disease and constitute novel and resilient solutions that resisted the negative selection process
2. **No alternative, No competition:** Lack of understanding of the organic nature of the disease, of solid diagnostic criteria, no treatment or cure, with no dedicated market & competition
3. **Strong Patient Association Collaborative Environment:** *CADI-T1031 Diagnostic/Treatment is an in-depth co-construction with the French ME/CFS Patient Association and the support of the European ME/CFS Alliance.*
4. **Covid-19 Accelerator:** There is an imminent necessity for the treatment because of the exploding number of Covid-19 long-haulers that are on the verge of developing ME/CFS
5. **Expand to a Vast Market:** ME/CFS treatment consists the basis for the treatment of other CLGIDs, including Gulf War Syndrome, Fibromyalgia, chronic injury & muscle wear. CADI treatments already identified.

With a world's first in neurodegenerative diseases, *1 therapeutic spin-off and 1 exclusive out-license*, Telesphore Pharma confirms the excellence of BMSystems to deliver value to patients and shareholders.

This event will also be the opportunity for Bio-Modeling Systems to present its two complementary business targets:

- **For R&D, Translational Medicine & Digital Health Executives**, we offer *robust alternative decision-making to de-risk, save time and costs* of R&D and Digital Health programs,
- **For Business Developers, Patients Groups & Investors**, we discover *novel low-risk, highly effective and cost-effective* diagnostics, therapy, nutrition, cosmetics, bioprocess solutions for spin-offs or out-licensing

Do not hesitate to contact us for more information or any business request the *B to B partnering platform*.

We warmly invite you to visit our *new website* to discover our achievements and potential

Best regards,

Manuel GEA
CEO Bio-Modeling Systems

***CADI: Computer Assisted Deductive Integration**

About Bio-Modeling Systems

Bio-Modeling Systems is the world's first Mechanisms-Based medicine company that changed the discovery paradigm to create novel medical meanings from unreliable heterogeneous sources of data to generate validated & directly exploitable first in class heuristic non-mathematical mechanistic CADI™ models. Bio-Modeling Systems is a 100% biology driven company focused on discovery, and critical high impact decisions making and address the following Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health with its dual business model: Contractual or Collaborative R&D programs. *For all details and presentations, visit our website.*

We propose to R&D & Translational Medicine Executives, robust alternative decision-making to de-risk, save time, costs, and novel cost-effective diagnostics/therapies for their businesses.

List-Unsubscribe: if you do not want to receive other information from us